BBC : reported that Three countries get first malaria vaccine

It is why the WHO is running pilots in three countries to see if a full malaria vaccine programme could be started. Dr Matshidiso Moeti, the WHO regional director for Africa, said: "The prospect of a malaria vaccine is great news. Image copyright D Poland/PATH Image caption The vaccine has been tested extensively in more than 15,000 childrenThe world's first vaccine against malaria will be introduced in three countries - Ghana, Kenya and Malawi - starting in 2018. Malaria vaccine: How good is good enough? "Combined with existing malaria interventions, such a vaccine would have the potential to save tens of thousands of lives in Africa."

Ghana, Kenya and Malawi to pilot GSK malaria vaccine from 2018

RTS,S was developed by GSK in partnership with the non-profit PATH Malaria Vaccine Initiative and part-funded by the Bill & Melinda Gates Foundation. LONDON Ghana, Kenya and Malawi will pilot the world's first malaria vaccine from 2018, offering it for babies and children in high-risk areas as part of real-life trials, the World Health Organization said on Monday. "Combined with existing malaria interventions, such a vaccine would have the potential to save tens of thousands of lives in Africa." The injectable vaccine, called RTS,S or Mosquirix, was developed by British drugmaker GlaxoSmithKline to protect children from the most deadly form of malaria in Africa. The WHO said Malawi, Kenya and Ghana were chosen for the pilot due to several factors, including having high rates of malaria as well as good malaria programs, wide use of bed-nets, and well-functioning immunization programs.

Ghana, Kenya and Malawi to pilot GSK malaria vaccine from 2018

RTS,S was developed by GSK in partnership with the non-profit PATH Malaria Vaccine Initiative and part-funded by the Bill & Melinda Gates Foundation. The WHO pilot programme will assess whether the Mosquirix's protective effect in children aged 5 to 17 months can be replicated in real-life. "Combined with existing malaria interventions, such a vaccine would have the potential to save tens of thousands of lives in Africa." The WHO said Malawi, Kenya and Ghana were chosen for the pilot due to several factors, including having high rates of malaria as well as good malaria programmes, wide use of bed-nets, and well-functioning immunisation programmes. The injectable vaccine, called RTS,S or Mosquirix, was developed by British drugmaker GlaxoSmithKline to protect children from the most deadly form of malaria in Africa.


collected by :Lucy William

To follow all the new news about Health care